Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 4178-4183

  Kao, Yu Hsun ^a,b   Liou, Jing Ping ^b   Chung, Cheng Chich ^a,b   Lien, Gi Shih ^a   Kuo, Ching Chuan ^c   Chen, Shih Ann ^d,e   Chen, Yi Jen ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Angiotensin II type I receptor; Fibroblast; Heart failure; Histone deacetylases; Transforming growth factor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IIDELTA; HISTONE DEACETYLASE INHIBITOR; ISOPRENALINE; MPT 0E 014; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME INHIBITION; FIBROBLAST; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC HEART FAILURE;

ANGIOTENSIN II TYPE I RECEPTOR; FIBROBLAST; HEART FAILURE; HISTONE DEACETYLASES; TRANSFORMING GROWTH FACTOR-Β;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CELLS, CULTURED; HEART FAILURE; HISTONE DEACETYLASE INHIBITORS; MALE; MYOCARDIAL CONTRACTION; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 84886307237     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.111     Document Type: Article

References (32)

1. K.K. Ho, J.L. Pinsky, W.B. Kannel, and D. Levy The epidemiology of heart failure: the Framingham Study J Am Coll Cardiol 22 1993 6A 13A
2. P. Jong, E. Vowinckel, P.P. Liu, Y. Gong, and J.V. Tu Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study Arch Intern Med 162 2002 1689 1694
3. M.V. Latronico, L. Elia, G. Condorelli, and D. Catalucci Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment Int J Biochem Cell Biol 40 2008 1643 1648
4. A. Granger, I. Abdullah, and F. Huebner Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice FASEB J 22 2008 3549 3560
5. T.A. McKinsey Therapeutic potential for HDAC inhibitors in the heart Annu Rev Pharmacol Toxicol 52 2012 303 319
6. P.A. Marks Discovery and development of SAHA as an anticancer agent Oncogene 26 2007 1351 1356
7. C. Grant, F. Rahman, and R. Piekarz Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors Expert Rev Anticancer Ther 10 2010 997 1008
8. M. Duvic, and C. Zhang Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma Br J Cancer 95 2006 S13 S19
9. T.A. McKinsey Targeting inflammation in heart failure with histone deacetylase inhibitors Mol Med 17 2011 434 441
10. J.P. Cardinale, S. Sriramula, and R. Pariaut HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats Hypertension 56 2010 437 444
11. H. Kook, J.J. Lepore, and A.D. Gitler Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop J Clin Invest 112 2003 863 871
12. A. Iyer, A. Fenning, and J. Lim Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats Br J Pharmacol 159 2010 1408 1417
13. H.J. Kee, I.S. Sohn, and K.I. Nam Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding Circulation 113 2006 51 59
14. T.M. Lee, M.S. Lin, and N.C. Chang Inhibition of histone deacetylase on ventricular remodeling in infarcted rats Am J Physiol Heart Circ Physiol 293 2007 H968 H977
15. M.G. Sutton, and N. Sharpe Left ventricular remodeling after myocardial infarction: pathophysiology and therapy Circulation 101 2000 2981 2988
16. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease J Clin Invest 117 2007 568 575
17. D. Hasper, M. Hummel, F.X. Kleber, I. Reindl, and H.D. Volk Systemic inflammation in patients with heart failure Eur Heart J 19 1998 761 765
18. F. Zannad, F. Alla, B. Dousset, A. Perez, and B. Pitt Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation 102 2000 2700 2706
19. P. Uusimaa, J. Risteli, and M. Niemela Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency Circulation 96 1997 2565 2572
20. F. Liu, M.D. Levin, and N.B. Petrenko Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin J Mol Cell Cardiol 45 2008 715 723
21. M.J. Lai, H.L. Huang, and S.L. Pan Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo J Med Chem 55 2012 3777 3791
22. H.Y. Lee, C.R. Yang, and M.J. Lai 1-Arylsulfonyl-5-(N-hydroxyacrylamide) indolines histone deacetylase inhibitors are potent cytokine release suppressors Chembiochem 14 2013 1248 1254
23. H.L. Huang, H.Y. Lee, and A.C. Tsai Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells PLoS One 7 2012 e43645
24. 2 +-ATPase and calcium homeostasis in cardiac myocytes Lab Invest 91 2011 1291 1297
25. C.C. Liang, A.Y. Park, and J.L. Guan In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nat Protoc 2 2007 329 333
26. M. Pang, and S. Zhuang Histone deacetylase: a potential therapeutic target for fibrotic disorders J Pharmacol Exp Ther 335 2010 266 272
27. Y. Kong, P. Tannous, and G. Lu Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy Circulation 113 2006 2579 2588
28. A. Leask Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation Circ Res 106 2010 1675 1680
29. S. Rosenkranz TGF-β1 and angiotensin networking in cardiac remodeling Cardiovasc Res 63 2004 423 432
30. J. Backs, T. Backs, and S. Neef The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload Proc Natl Acad Sci 106 2009 2342 2347
31. M.E. Anderson, J.H. Brown, and D.M. Bers CaMKII in myocardial hypertrophy and heart failure J Mol Cell Cardiol 51 2011 468 473
32. J. Luo, X. Gao, L. Peng, H. Sun, and G. Dai Effects of hydrochlorothiazide on cardiac remodeling in a rat model of myocardial infarction-induced congestive heart failure Eur J Pharmacol 667 2011 314 321